Press Releases for FRX

Press Releases
AstraZeneca: Third Quarter and Nine Months Results 2009
Pappas Ventures Names Eric Linsley Managing Partner
Forest Laboratories, Inc. And Nycomed Announce a Conference Call to Review Publication of Daxas® Phase III Clinical Trial Results
Nycomed and Forest Laboratories to Collaborate on Daxas® (roflumilast) for COPD
Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD
Biotech Hot in July Driven By Positive Drug Data and Acquisitions
Forest Laboratories, Inc. Reports Fiscal First Quarter 2010 Earnings Per Share of $0.87
Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 First Quarter Earnings
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
Cypress Bioscience, Inc. Announces First Quarter 2009 Financial Results
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Fourth Quarter Earnings
Zacks Analyst Blog Highlights: Forest Laboratories Inc, General Motors Corp, DryShips Inc, Nissan Motor Co and Citi Trends Inc.
Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
Zacks Analyst Blog Highlights: Cypress Biosciences, Forest Labs, ArvinMeritor, Apogee Enterprises and The Macerich Company - Mar 18 2009 11:51PM
Zacks Analyst Blog Highlights: Cypress Biosciences, Forest Labs, ArvinMeritor, Apogee Enterprises and The Macerich Company - Mar 18 2009 7:17AM
USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
Zacks Analyst Blog Highlights: Allianz Aktiengesell, Advanced Micro Devices, Inc., Schlumberger Limited, Forest Labs and Cypress Biosciences.
Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
Zacks Analyst Blog Highlights: Qualcomm, Inc., Nokia, Johnson & Johnson, Cypress Bioscience, Inc. And Forest Laboratories, Inc.
Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression
Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Forest Laboratories Responds To Unsolicited Mini-Tender Offer
USPTO Confirms Validity of Bystolic(R) Patent
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
Zacks Analyst Blog Highlights: Wipro Ltd., Robert Half International Inc., Monarch Casino & Resort Inc., Forest Labs, Inc. And Critical Therapeutics Inc.
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
FDA Defers Final Action on milnacipran New Drug Application
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings - Oct 6 2008 11:43AM
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings - Oct 1 2008 6:03PM
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
Forest Laboratories, Inc. Appoints Frank Murdolo, Vice President - Investor Relations
USPTO Office Action in the Reexamination of U.S. Patent No. 6,545,040
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Forest Laboratories, Inc. Reports Fiscal First Quarter 2009 Earnings Per Share of $0.79, Including $0.08 per Share Charge for Agreement Termination
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results - Jun 3 2008 3:18AM
Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results - May 27 2008 12:59AM
Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD - May 27 2008 12:58AM
Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD - Jun 3 2008 3:18AM
/C O R R E C T I O N -- Forest Laboratories, Inc./ - Jun 3 2008 3:17AM
/C O R R E C T I O N -- Forest Laboratories, Inc./ - May 27 2008 12:55AM
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress - May 27 2008 12:54AM
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress - Jun 3 2008 3:17AM
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement - Jun 3 2008 3:15AM
Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents - Jun 3 2008 3:14AM
BellwetherReport.com Initiates Analyst Coverage on STT, FRX, AVT and KCI
Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings